fashion -WSS

fashion

author：knowledge 2025-09-02 11:40:51 - browse：16

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

In December, Vertex Pharmaceuticalsannounced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain. This quarter, the company will read out results from Phase 3 studies of the same pain drug, called VX-548, in people with acute pain following surgery.

The next big test of Alnylam Pharmaceuticals’pipeline of RNA-interference medicines looms with the outcome of a Phase 3 study called HELIOS-B that is investigating vutrisiran as a treatment for ATTR-CM, a progressive disease that leads to heart failure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Histogen: Failed biotech offers rare public look inside

knowledge

WSS

There's an unseen cost to disruptive road

FDA sets aggressive timeline for overhauling inspection procedures

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

There's an unseen cost to disruptive road

Maisha Meds is a PBM, but don't call it that

Chan Zuckerberg Biohub Chicago to focus on inflammation

entertainment

fashion

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Flu vaccine reformulation won't be easy, manufacturers warn

In age of alternative facts, a scholarly course on calling out crap

Chan Zuckerberg Biohub Chicago to focus on inflammation

Apple is now the first public company to be valued at $3 trillion

CVS is on a mission to consolidate health care. Will it work?

What does generative AI mean for health care? We asked experts

Flu vaccine reformulation won't be easy, manufacturers warn

Guidelines to prevent youth baseball injuries need more muscle

A virus, fished out of a lake, may have saved a man’s life

hotspot

Was Amgen transparent enough on FDA's concern on cancer drug?

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Analysis of telehealth claims data suggest service duplication

A virus, fished out of a lake, may have saved a man’s life

A virus, fished out of a lake, may have saved a man’s life

Was Amgen transparent enough on FDA's concern on cancer drug?

hotspot

knowledge

focus

explore